Skip to content
akaturk Academic measurement
Search

Article detail · 2022 · article

The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort

Journal Frontiers Media SA
ISSN3611-7966
YÖKSİS OpenAlex Open access · gold
Year2022
Citations3OpenAlex
Percentile%48.7
FWCI0.21.00 = world average

Data source split

  • YÖKSİSYÖKSİS article record
  • YÖKSİS venueFrontiers Media SA
  • OpenAlexOpenAlex enrichment (abstract, citations, topics)
  • Semantic Scholarcitation count (not merged with OpenAlex)

Abstract

OpenAlex English

Background and objectives Although several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. Methods Patients admitted to 26 different hospitals located in 16 different provinces between March 11–July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. Results We retrospectively evaluated 1,472 COVID-19 adult patients; 57.1% were men (mean age = 51.9 ± 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5–12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (β [95% CI]: 4.71 [2.31–7.11]; p = 0.001), favipiravir (β [95% CI]: 3.55 [2.56–4.55]; p = 0.001) and HCQ (β [95% CI]: 0.84 [0.02–1.67]; p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70–5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28–6.75]; p = 0.011). Conclusion Our findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

3citationsOpenAlex · cited_by_count (cache / database)

1 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. 2026 Retrospective analysis of the efficacy of molnupiravir and favipiravir in COVID-19 patients admitted to intensive care unitCitations 0 · OpenAlex

Authors

69
  1. CENK BABAYİĞİT 1
  2. NURDAN KÖKTÜRK 2
  3. SEVAL KUL HALTER GAZİANTEP ÜNİVERSİTESİ 3
  4. PELİN DURU ÇETİNKAYA 4
  5. SİBEL ATİŞ NAYCİ 5
  6. SERAP ARGUN BARIŞ 6
  7. OĞUZ KARCIOĞLU 7
  8. PINAR AYSERT YILDIZ 8
  9. İLİM IRMAK 9
  10. AYCAN AKBAŞ YÜKSEL 10
  11. YONCA SEKİBAĞ 11
  12. OYA BAYDAR TOPRAK 12
  13. EMEL AZAK KARALİ 13
  14. SAİT MULAMAHMUTOĞLU 14
  15. ÇAĞLAR ÇUHADAROĞLU 15
  16. ASLIHAN DEMİREL 16
  17. BUĞRA KERGET 17
  18. BURCU BARAN KETENCİOGLU 18
  19. HASAN SELÇUK ÖZGER 19
  20. GÜLCİHAN ÖZKAN 20
  21. ZEYNEP TÜRE 21
  22. BEGÜM ERGAN 22
  23. VİLDAN AVKAN OĞUZ 23
  24. OĞUZ KILINÇ 24
  25. MERVE ERÇELİK KONCAK 25
  26. TANSU ULUKAVAK ÇİFTÇİ 26
  27. ÖZLEM ALICI 27
  28. ESRA NURLU TEMEL 28
  29. ÖZLEM ATAOĞLU DÜZCE ÜNİVERSİTESİ 29
  30. ASENA ÇEKEN 30
  31. DİLEK ÇETİNER BAHÇETEPE 31
  32. YUSUF TAHA GÜLLÜ 32
  33. FÜSUN FAKILI GAZİANTEP ÜNİVERSİTESİ 33
  34. FİGEN DEVECİ 34
  35. NESLİHAN KÖSE 35
  36. MÜGE MELTEM TOR 36
  37. GÜLŞAH GÜNLÜOĞLU 37
  38. SEDAT ALTIN 38
  39. TEYFİK TURGUT 39
  40. NAZMİYE TİBEL TUNA 40
  41. ÖNDER ÖZTÜRK 41
  42. ÖNER DİKENSOY KOÇ ÜNİVERSİTESİ 42
  43. PINAR YILDIZ 43
  44. İLKNUR BAŞYİĞİT 44
  45. HAŞİM BOYACI 45
  46. İPEK KIVILCIM OĞUZÜLGEN 46
  47. ŞERMİN BÖREKÇİ 47
  48. BİLUN GEMİCİOĞLU 48
  49. FIRAT BAYRAKTAR 49
  50. OSMAN ELBEK 50
  51. İSMAİL HANTA 51
  52. HACER KUZU OKUR 52
  53. GÜLSEREN SAĞCAN 53
  54. OĞUZ UZUN ONDOKUZ MAYIS ÜNİVERSİTESİ 54
  55. METİN AKGÜN 55
  56. GÖKSEL ALTINIŞIK ERGUR 56
  57. ADİLE BERNA DURSUN 57
  58. EBRU ÇAKIR EDİS 58
  59. SELİM ŞAKİR ERKMEN GÜLHAN 59
  60. FUSUN ÖNER EYÜBOĞLU 60
  61. ÖKKEŞ GÜLTEKİN 61
  62. YAVUZ HAVLUCU 62
  63. METİN ÖZKAN 63
  64. AYŞIN ŞAKAR COŞKUN 64
  65. ABDULLAH SAYINER 65
  66. ALİ FUAT KALYONCU 66
  67. BAHRİYE OYA İTİL 67
  68. HASAN BAYRAM 68
  69. GÜLCİHAN ZEHRA YAVAŞOĞLU İSTANBUL NİŞANTAŞI ÜNİVERSİTESİ 69